Castle Biosciences CSTL Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's investing cash flow?
- Castle Biosciences (CSTL) reported investing cash flow of -$25.8M in Q1 2026.
- How has Castle Biosciences's investing cash flow changed year-over-year?
- Castle Biosciences's investing cash flow decreased by 15.0% year-over-year, from -$22.43M to -$25.8M.
- What is the long-term trend for Castle Biosciences's investing cash flow?
- Over 2 years (2021 to 2023), Castle Biosciences's investing cash flow has grown at a -50.7% compound annual growth rate (CAGR), from -$66.66M to -$16.18M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.